| Dr Joseph A Kuchler, MD | |
|
3 Cooper Plz Ste 104&403, Camden, NJ 08103-1438 | |
| (856) 342-2141 | |
| (856) 968-7082 |
| Full Name | Dr Joseph A Kuchler |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 50 Years |
| Location | 3 Cooper Plz Ste 104&403, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538117189 | NPI | - | NPPES |
| 1469401 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 25MA03037600 (New Jersey) | Secondary |
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 25MA03037600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holy Redeemer Home Care | Runnemede, NJ | Home health agency |
| Cooper University Hospital | Camden, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cooper Surgical Associates, Pa | 3274430764 | 218 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
| Entity Name | Virtua Surgical Group, P.a |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184811945 PECOS PAC ID: 7315850138 Enrollment ID: O20031107000528 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
| Entity Name | Cooper Surgical Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427177195 PECOS PAC ID: 3274430764 Enrollment ID: O20031213000037 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
| Entity Name | Atlanticare Physician Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093829608 PECOS PAC ID: 8527953660 Enrollment ID: O20040218000405 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph A Kuchler, MD 1 Federal St # 200, Camden, NJ 08103-1088 Ph: (856) 356-4924 | Dr Joseph A Kuchler, MD 3 Cooper Plz Ste 104&403, Camden, NJ 08103-1438 Ph: (856) 342-2141 |
News Archive
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced disease, rather than treatment differences, according to a study in the July 24/31 issue of JAMA.
› Verified 9 days ago
Richard Y Highbloom, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3 Cooper Plz, Suite 403, Camden, NJ 08103 Phone: 856-342-3113 | |
Michael Rosenbloom, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 3 Cooper Plaza, Suite 403, Camden, NJ 08103 Phone: 856-342-3113 Fax: 856-541-5379 | |
Dr. Anthony J. Delrossi, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 3 Cooper Plz, Suite 411, Camden, NJ 08103 Phone: 856-342-3113 |